Table 1

Logistic regression model comparing the prevalence of macrovascular, microvascular and kidney complications in individuals at high, intermediate or low (reference category) probability of liver fibrosis or steatosis

Cardiovascular eventeGFR EPI-CKD (cut-off 60)MicroalbuminuriaDiabetic retinopathy
OR95% CIP valueOR95% CIP valueOR95% CIP valueOR95% CIP value
FLI
 Low1--1--1--1--
 Middle1.651.13 to 2.400.0091.651.03 to 2.680.0382.911.65 to 5.14<0.0010.830.46 to 1.500.542
 High1.320.94 to 1.850.1101.771.15 to 2.720.0103.492.05 to 5.94<0.0011.050.63 to 1.760.858
HSI
 Low1--1--1--1--
 Middle4.890.50 to 47.610.1711.510.15 to 14.780.725--0.999--0.999
 High0.920.73 to 1.180.5180.610.47 to 0.840.0020.950.68 to 1.350.7620.8250.54 to 1.310.408
NAFLD Ridge Score
 Low1--1--1--1--
 Middle0.520.25 to 1.150.1080.510.22 to 1.170.1101.200.39 to 3.680.7500.990.24 to 4.100.986
 High0.950.48 to 1.890.8940.570.28 to 1.160.1181.790.67 to 4.810.2481.500.44 to 5.130.520
AST/ALT
 Low1--1--1--1--
 Middle1.731.42 to 2.10<0.0012.041.59 to 2.60<0.0010.940.73 to 1.200.5941.581.09 to 2.270.015
 High1.861.37 to 2.54<0.0013.762.67 to 5.31<0.0011.400.95 to 2.060.0902.681.61 to 4.48<0.001
APRI
 Low1--1--1--1--
 Middle1.260.98 to 1.620.0681.190.90 to 1.570.2251.090.78 to 1.500.6110.900.57 to 1.430.662
 High0.940.26 to 3.360.9190.720.15 to 3.460.6772.380.33 to 17.020.387--0.999
FIB-4
 Low1--1--1--1--
 Middle2.031.63 to 2.54<0.0012.782.14 to 3.62<0.0011.020.77 to 1.350.8791.120.77 to 1.640.548
 High2.621.69 to 4.04<0.0016.394.05 to 10.08<0.0011.580.91 to 2.720.1021.580.77 to 3.230.214
NAFLD fibrosis score
 Low1--1--1--1--
 Middle1.760.91 to 3.400.0960.980.46 to 2.090.9631.780.75 to 4.240.1901.440.45 to 4.550.537
 High2.031.01 to 4.080.0462.171.00 to 4.670.0491.740.71 to 4.240.2241.960.60 to 6.420.264
  • Values in bold are statistically significant.

  • APRI, AST to Platelet Ratio Index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4; FLI, Fatty Liver Index; HSI, Hepatic Steatosis Index; NAFLD, non-alcoholic fatty liver disease.